Geode Capital Management LLC Raises Stock Holdings in Fulcrum Therapeutics, Inc. (NASDAQ:FULC)

Geode Capital Management LLC raised its position in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) by 1.0% during the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 1,320,862 shares of the company’s stock after acquiring an additional 13,485 shares during the quarter. Geode Capital Management LLC owned approximately 2.12% of Fulcrum Therapeutics worth $4,716,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. National Bank of Canada FI increased its stake in Fulcrum Therapeutics by 869.6% in the 2nd quarter. National Bank of Canada FI now owns 4,460 shares of the company’s stock worth $28,000 after buying an additional 4,000 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its stake in Fulcrum Therapeutics by 64.4% during the third quarter. China Universal Asset Management Co. Ltd. now owns 12,002 shares of the company’s stock valued at $43,000 after buying an additional 4,701 shares during the last quarter. SG Americas Securities LLC grew its holdings in Fulcrum Therapeutics by 26.5% during the 3rd quarter. SG Americas Securities LLC now owns 33,019 shares of the company’s stock valued at $118,000 after buying an additional 6,926 shares in the last quarter. Profund Advisors LLC bought a new stake in Fulcrum Therapeutics in the second quarter worth $68,000. Finally, American Century Companies Inc. lifted its holdings in shares of Fulcrum Therapeutics by 13.2% in the 2nd quarter. American Century Companies Inc. now owns 104,371 shares of the company’s stock valued at $647,000 after acquiring an additional 12,167 shares during the last quarter. 89.83% of the stock is currently owned by institutional investors.

Fulcrum Therapeutics Price Performance

Shares of FULC stock opened at $5.08 on Monday. The company has a market cap of $274.01 million, a price-to-earnings ratio of -16.39 and a beta of 2.06. Fulcrum Therapeutics, Inc. has a 1-year low of $2.86 and a 1-year high of $13.70. The stock has a 50 day simple moving average of $3.85 and a 200-day simple moving average of $5.58.

Analyst Ratings Changes

Several equities analysts recently commented on FULC shares. Stifel Nicolaus downgraded shares of Fulcrum Therapeutics from a “buy” rating to a “hold” rating and cut their price target for the company from $22.00 to $3.00 in a report on Thursday, September 12th. Bank of America cut Fulcrum Therapeutics from a “neutral” rating to an “underperform” rating and dropped their price objective for the stock from $10.00 to $2.00 in a research note on Thursday, September 12th. HC Wainwright reaffirmed a “neutral” rating and issued a $4.00 price objective on shares of Fulcrum Therapeutics in a research note on Thursday, November 14th. Leerink Partners reissued a “market perform” rating and issued a $4.00 price objective on shares of Fulcrum Therapeutics in a research note on Thursday, September 12th. Finally, Cantor Fitzgerald lowered Fulcrum Therapeutics from an “overweight” rating to a “neutral” rating in a research note on Thursday, September 12th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and an average price target of $9.33.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.